| Home : Quantum Leap Healthcare Collaborative Announces the Selection of Sanofi's SAR439859 as the oral SERD Backbone Agent in the Endocrine Optimization Pilot Study of the I-SPY 2 TRIAL for Clinically High Risk, Molecularly Low Risk Stage 2/3 Breast Cancer |
|
Jun 08
2020 |
Quantum Leap Healthcare Collaborative Announces the Selection of Sanofi's SAR439859 as the oral SERD Backbone Agent in the Endocrine Optimization Pilot Study of the I-SPY 2 TRIAL for Clinically High Risk, Molecularly Low Risk Stage 2/3 Breast Cancer |
|
SAN FRANCISCO, June 8, 2020 /PRNewswire/ -- Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today an evaluation of SAR439859, an oral estrogen receptor degrader (SERD) in a new I-SPY 2 study arm targeting patients with newly diagnosed hormone receptor-positive (HR+)... |
|
|
|
| Source:https://www.prnewswire.com:443/news-releases/quantum-leap-healthcare-collaborative-announces-the-selection-of-sanofis-sar439859-as-the-oral-serd-backbone-agent-in-the-endocrine-optimization-pilot-study-of-the-i-spy-2-trial-for-clinically-high-risk-molecul |
| |
|
Related News
|
» GATE Energy Continues Global Expansion with New Office in South Korea
» With recovery of last case, New Zealand has eradicated virus
|
